We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
76
DELISTED
Amicus Therapeutics
FOLD
$5.18M 0.43%
613,500
+47,000
+8% +$333K
ASND icon
77
Ascendis Pharma A/S
ASND
$16.8B
$5.01M 0.42%
270,000
– –
XNPT
78
DELISTED
XENOPORT, INC.
XNPT
$4.96M 0.42%
1,100,000
– –
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.56B
$4.9M 0.41%
56,250
– –
CORV
80
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$4.87M 0.41%
1,190,000
– –
AGN.PRA
81
DELISTED
Allergan plc
AGN.PRA
$4.58M 0.38%
5,000
– –
CGEN icon
82
Compugen
CGEN
$228M
$4.58M 0.38%
820,000
+15,000
+2% +$78.3K
KA
83
DELISTED
Kineta, Inc. Common Stock
KA
$4.53M 0.38%
+3,357
New +$3.7M
CHMA
84
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.51M 0.38%
492,500
+5,000
+1% +$54.1K
NVAX icon
85
Novavax
NVAX
$1.31B
$4.4M 0.37%
42,625
+4,125
+11% +$442K
KYNB
86
Kyntra Bio
KYNB
$29.4M
$4.34M 0.36%
8,160
+560
+7% +$279K
MGNX icon
87
MacroGenics
MGNX
$257M
$4.22M 0.35%
225,000
+7,000
+3% +$133K
AIMT
88
DELISTED
Aimmune Therapeutics
AIMT
$3.97M 0.33%
293,000
+33,354
+13% +$520K
AVXS
89
DELISTED
AveXis, Inc. Common Stock
AVXS
$3.89M 0.33%
+142,758
New +$3.12M
PRGO icon
90
Perrigo
PRGO
$1.78B
$3.84M 0.32%
30,000
– –
GNCA
91
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.71M 0.31%
60,000
– –
KITE
92
DELISTED
Kite Pharma, Inc.
KITE
$3.67M 0.31%
80,000
– –
OTIC
93
DELISTED
Otonomy, Inc.
OTIC
$3.58M 0.3%
240,000
+42,500
+22% +$668K
PTLA
94
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.57M 0.3%
175,000
+10,000
+6% +$317K
NBRV
95
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.4M 0.29%
1,520
+580
+62% +$1.25M
PRTK
96
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.38M 0.28%
223,000
+192,173
+623% +$2.94M
CDTX
97
DELISTED
Cidara Therapeutics
CDTX
$3.17M 0.27%
12,500
– –
DVAX
98
DELISTED
Dynavax Technologies
DVAX
$3.17M 0.27%
165,000
+15,000
+10% +$303K
NVCR icon
99
NovoCure
NVCR
$1.91B
$3.1M 0.26%
214,316
– –
GI
100
DELISTED
EndoChoice Holdings, Inc.
GI
$3.07M 0.26%
590,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.